Screening for colorectal cancer and evolving issues for physicians and patients: A review

JAMA - Journal of the American Medical Association

Volumn 316, Issue 20, 2016, Pages 2135-2145

  Lieberman, David ^a   Ladabaum, Uri ^b   Cruz Correa, Marcia ^c   Ginsburg, Carla ^d   Inadomi, John M ^e   Kim, Lawrence S ^f   Giardiello, Francis M ^g   Wender, Richard C ^h,i  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS   (Puerto Rico)

^d NEWTON WELLESLEY HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f South Denver Gastroenterology   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h AMERICAN CANCER SOCIETY   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ADENOMATOUS POLYP; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CAUSE OF DEATH; COLONOSCOPY; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DECISION MAKING; DNA DETERMINATION; FECAL IMMUNOCHEMICAL TEST; FECES ANALYSIS; GENERAL PRACTITIONER; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAID; MEDICARE; OCCULT BLOOD TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SIGMOIDOSCOPY; ULCERATIVE COLITIS; UNITED STATES; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; EVIDENCE BASED MEDICINE; MASS SCREENING; MIDDLE AGED; MORTALITY; OCCULT BLOOD; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS;

COLONOSCOPY; COLORECTAL NEOPLASMS; DECISION MAKING; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; HUMANS; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PHYSICIANS, PRIMARY CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGMOIDOSCOPY;

EID: 85006118739     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.17418     Document Type: Review

References (63)

1. American Cancer Society. Cancer Facts & Figures 2016. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf. Accessed August 19, 2016.
2. Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348(9040):1472-1477.
3. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467-1471.
4. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood: Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328(19):1365-1371.
5. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343(22): 1603-1607.
6. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369(12):1106-1114.
7. Segnan N, Armaroli P, Bonelli L, et al; SCORE Working Group. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial-SCORE. J Natl Cancer Inst. 2011;103(17):1310-1322.
8. Schoen RE, Pinsky PF,Weissfeld JL, et al; PLCO Project Team. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366(25):2345-2357.
9. AtkinWS, Edwards R, Kralj-Hans I, et al; UK Flexible Sigmoidoscopy Trial Investigators. Once only flexible sigmoidsocopy screening in prevention of colorectal cancer: A multicentre randomized controlled trial. Lancet. 2010;375:1624-1633.
10. Holme O, Løberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer screening on colorectal cancer incidence and mortality: A randomized clinical trial. JAMA. 2014; 312:606-615.
11. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366(8):687-696.
12. Klabunde C, Brown M, Ballard-Barbash R, et al; Centers for Disease Control and Prevention (CDC). Cancer screening-United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61(3):41-45.
13. Bibbins-Domingo K, Grossman DC, Curry SJ, et al; US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2016; 315(23):2564-2575.
14. Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of benefits, burden and harms for colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force. JAMA. 2016;315(23):2595-2609.
15. Levin B, Lieberman DA, McFarland B, et al; American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134(5):1570-1595.
16. Qaseem A, Denberg TD, Hopkins RH Jr, et al; Clinical Guidelines Committee of the American College of Physicians. Screening for colorectal cancer: A guidance statement from the American College of Physicians. Ann Intern Med. 2012;156(5): 378-386.
17. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: A randomized clinical trial of competing strategies. Arch Intern Med. 2012;172(7):575-582.
18. Brett AS. Flexible sigmoidoscopy for colorectal cancer screening: more evidence, persistent ironies. JAMA. 2014;312(6):601-602.
19. Steinwachs D, Allen JD, BarlowWE, et al. National Institutes of Health State-of-The-Science Conference Statement: Enhancing Use and Quality of Colorectal Cancer Screening. Ann Intern Med. 2010;152(10):663-667.
20. Subramanian S, Klosterman M. Amonkar MM, Hunt TL. Adherence with colorectal cancer screening guidelines: A review. Prev Med. 2004;38: 536-550.
21. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(9):627-637.
22. Henley SJ, Singh SD, King J, Wilson R, O'Neil ME, Ryerson AB; Centers for Disease Control and Prevention. Invasive cancer incidence and survival-United States, 2011. MMWR Morb Mortal Wkly Rep. 2015;64(9):237-242.
23. Carethers JM. Screening for colorectal cancer in African Americans: determinants and rationale for an earlier age to commence screening. Dig Dis Sci. 2015;60(3):711-721.
24. Zauber AG. The impact of screening on colorectal cancer mortality and incidence: has it really made a difference? Dig Dis Sci. 2015;60(3): 681-691.
25. Nishihara R,Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369(12):1095-1105.
26. Løberg M, Kalager M, Holme O, Hoff G, Adami HO, Bretthauer M. Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med. 2014;371(9):799-807.
27. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology. 2010;138(6): 2029-2043.e10.
28. Kahi CJ, Boland CR, Dominitz JA, et al; United States Multi-Society Task Force on Colorectal Cancer. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016;150(3):758-768.e11.
29. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR; United States Multi-Society Task Force on Colorectal Cancer. Guidelines for colonoscopy surveillance after screening and polypectomy: A consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143(3):844-857.
30. Farraye FA, Odze RD, Eaden J, et al; AGA Institute Medical Position Panel on Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):738-745.
31. Giardiello FM, Allen JI, Axilbund JE, et al; US Multi-Society Task Force on Colorectal Cancer. Guidelines on genetic evaluation and management of Lynch syndrome: A consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology. 2014;147(2):502-526.
32. Lowery JT, Ahnen DJ, Schroy PC III, et al Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A state of the science review. Cancer 2016;122(17): 2633-2645..
33. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160(3):171-181.
34. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135(1):82-90.
35. Segnan N, Senore C, Andreoni B, et al; SCORE3 Working Group-Italy. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology. 2007;132(7):2304-2312.
36. Quintero E, Castells A, Bujanda L, et al; COLONPREV Study Investigators. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012; 366(8):697-706.
37. Hubbard RA, Johnson E, Hsia R, Rutter CM. The cumulative risk of false-positive fecal occult blood test after 10 years of colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2013; 22(9):1612-1619.
38. Moss SM, Campbell C, Melia J, et al. Performance measures in three rounds of the English bowel cancer screening pilot. Gut. 2012;61 (1):101-107.
39. Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, vonWagner C. Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme. Gut. 2015;64(2):282-291.
40. Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: A retrospective cohort study. Ann Intern Med. 2016;164(7):456-463.
41. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.
42. Johnson CD, Chen M-H, Toledano AY, et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med. 2008;359 (12):1207-1217.
43. Heresbach D, Djabbari M, Riou F, et al. Accuracy of computed tomographic colonography in a nationwide multicentre trial, and its relation to radiologist expertise. Gut. 2011;60(5):658-665.
44. Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst. 2010;102 (16):1238-1252.
45. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138(6):2088-2100.
46. Zalis ME, Barish MA, Choi JR, et al;Working Group on Virtual Colonoscopy. CT colonography reporting and data system: A consensus proposal. Radiology. 2005;236(1):3-9.
47. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med. 2007;357(22):2277-2284.
48. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150(1):1-8.
49. Doubeni CA,Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: A nested case-control study. Ann Intern Med. 2013;158(5 Pt 1):312-320.
50. Kahi CJ,Myers LJ, Slaven JE, et al. Lower endoscopy reduces colorectal cancer incidence in older individuals. Gastroenterology. 2014;146(3): 718-725.e3.
51. Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, Hoffmeister M. Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology. 2014; 146(3):709-717.
52. Bretthauer M, Kaminski MF, Loberg M, et al. Population-based colonoscopy screening for colorectal cancer: A randomized clinical trial. JAMA Intern Med. 2016;176(7):894-902.
53. Ko CW, Riffle S, Michaels L, et al. Serious complications within 30 days of screening and surveillance colonoscopy are uncommon. Clin Gastroenterol Hepatol. 2010;8(2):166-173.
54. Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009;150(12):849-857, W152.
55. Ranasinghe I, Parzynski CS, Searfoss R, et al. Difference in colonoscopy quality among facilities: development of a post-colonoscopy risk-standardized rate of unplanned hospital visits. Gastroenterology. 2016;150(1):103-113.
56. Lieberman D, Nadel M, Smith RA, et al. Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc. 2007;65(6):757-766.
57. Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. Am J Gastroenterol. 2015;110(1):72-90.
58. Lieberman D, Williams JL, Holub J, Morris C, Logan J, Carney P. Race, ethnicity and gender differences in risk of colorectal neoplasia in average-risk men and women: Implications for initiation age of colorectal cancer screening. Gastroenterology. 2014;147:351-358.
59. Regula J, Rupinski M, Kraszewska E, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006;355(18):1863-1872.
60. Ferlitsch M, Reinhart K, Pramhas S, et al. Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA. 2011; 306(12):1352-1358.
61. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM; American College of Gastroenterology. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104(3):739-750.
62. Lieberman DA, Holub JL, Morris CD, Logan J, Williams JL, Carney P. Low rate of large polyps (>9 mm) within 10 years after an adequate baseline colonoscopy with no polyps. Gastroenterology. 2014;147(2):343-350.
63. Acosta RD, Abraham NS, Chandrasekhara V, et al; ASGE Standards of Practice Committee. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc. 2016;83(1):3-16.